Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994;95(3):195-207.
doi: 10.1007/BF01271566.

Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study

Affiliations

Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study

J Reiriz et al. J Neural Transm Gen Sect. 1994.

Abstract

Microdialysis technique was used to study the effects of both acute and repeated oral administration of calcium-channel blockers (flunarizine, cinnarizine, verapamil, nifedipine and nicardipine) in dopaminergic function in rat brain and to compare them to the effects of haloperidol. Acute flunarizine, nicardipine or haloperidol increased extracellular levels of dopamine (DA) or metabolites. After repeated (18 days) administration, nicardipine, nifedipine, verapamil or haloperidol increased and flunarizine decreased extracellular striatal levels of dopamine or metabolites. Chronic treatment with calcium-channel blockers or haloperidol failed to block K(+)-evoked release of dopamine. This suggests that the calcium-channel blockers used in this study do not influence calcium entry necessary for DA release. An acute challenge with haloperidol caused either no change or a decrease in extracellular levels of DA or metabolites after repeated administration of calcium-channel blockers or haloperidol. This is considered to be due to the lesser response of dopaminergic neurons because of treatment. A neuroleptic-like mechanism of action together with a decrease in firing activity and/or a reduced dopamine re-uptake of dopaminergic neurons are considered.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Pharmacol. 1984 Oct 30;106(1):27-37 - PubMed
    1. Mol Pharmacol. 1979 Nov;16(3):877-85 - PubMed
    1. N Engl J Med. 1985 May 9;312(19):1261-2 - PubMed
    1. Neuropharmacology. 1987 Jan;26(1):101-5 - PubMed
    1. J Neurosci. 1985 Feb;5(2):297-306 - PubMed

Publication types